WO 2004/093662 PCT/US2004/006085

CLAIMS

- 1. A method for detecting prognosis of cancer, which comprises at least a step of detecting core-2 β1,6-N-acetylglucosaminyltransferase in a sample collected from a biological organism to examine the relationship between the results of the detection and the prognosis of cancer in the biological organism.
- 2. The method according to claim 1, wherein the core-2 β1,6-N-acetylglucosaminyltransferase is core-2 β1,6-N-acetylglucosaminyltransferase-I.
- 3. The method according to claim 1 or 2, wherein the biological organism is a human body.
- 4. The method according to any one of claims 1 to 3, wherein the sample is a living tissue.
- 5. The method according to any one of claims 1 to 4, wherein detecting of core-2 β 1,6-acetylglucosaminyltransferase is carried out by using a polypeptide capable of binding to core-2 β 1,6-N-acetylglucosaminyltransferase.
- 6. The method according to claim 5, wherein the polypeptide is an antibody or a polypeptide having its antigen-binding site.
- 7. The method according to any one of claims 1 to 6, wherein the cancer is one or at least two cancers selected from the group consisting of prostate cancer, testicular tumor and bladder cancer.

WO 2004/093662 PCT/US2004/006085

8. The method according to any one of claims 1 to 7, wherein the prognosis of cancer is possibility of cancer metastasis or recurrence.

- 9. The method according to any one of claims 1 to 8, which is carried out before resection of a cancer tissue.
- 10. The method according to claim 9, wherein the resection is total resection.
- 11. A kit for detecting prognosis of cancer, which comprises at least the following element (A):
- (A) a first polypeptide capable of binding to core-2 β 1,6-N-acetylglucosaminyltransferase.
- 12. The kit according to claim 11, which further comprises at least the following element (B):
- (B) a second polypeptide capable of specifically binding to the first polypeptide described in (A), and being labeled or capable of being labeled with a labeling substance.
- 13. The kit according to claim 11 or 12, wherein the polypeptide is an antibody or a polypeptide having its antigen-binding site.